ADVERTISING FEATURE
Planned Organ Preservation for Lower Rectal Cancer: Planning for a better Quality of Life.
NICE approved, Low Energy Contact X-Ray Brachytherapy (Papillon CXB) offers colorectal cancer patients the chance to avoid life-long stoma care.
Papillon CXB is a low energy (50KvP) X-ray treatment which delivers curative doses directly onto the cancer. Papillon CXB is now recognised by NICE and was part of a multi-centre, international trial, which looked to offer patients a non-surgical option, in the battle against colorectal cancer. The opportunity to offer planned organ preservation on the NHS is transforming the outlook for patients with lower rectal cancers both from a physical and mental wellbeing perspective. Not only does the patient avoid the time in hospital and the need for stoma care for life but, the NHS avoids all the costs associated with that ongoing care.
Breakthrough in Rectal Cancer Treatment. The published 5-year results of a recent clinical trial on the effectiveness of Papillon CXB, called OPERA, has demonstrated that operable patients diagnosed with rectal cancer up to and including T3a-b, can benefit from a less invasive approach using the Ariane Medical Systems Papillon+™ X-ray Brachytherapy system. Traditionally, rectal cancer treatment involves major surgery, often leading to life-altering consequences such as permanent stomas, requiring significant lifestyle adjustments for the patient. However, when combined with existing EBRT & Chemotherapy regimes, this cutting-edge treatment and technology provides a Total Neo-adjuvant Treatment (TNT) alternative, that preserves the organ and continued quality of life.
The study, widely reported in major media outlets
such as BBC News and The Independent, highlights the success of Papillon Contact X-ray Brachytherapy (CXB) in preventing the need for extensive surgical procedures. The findings indicate that this innovative approach delivers precise, high-dose radiation directly to the tumour site, effectively eradicating cancer cells while sparing healthy tissue.
Treating with the future in mind. Given the observed benefits of Papillon CXB in the OPERA trial, NICE amended their recommendations for the treatment of lower rectal tumours in November 2025 to encompass the majority of the OPERA trial protocols. Further research is underway to explore its role in combination with systemic therapies for more advanced rectal cancers. With the 5-year results published at the start of 2025, the future for the Papillon CXB treatment and patient choice and looks very positive with new sites opening in the UK as well as the USA and as far afield as India.
New Tech, Old Treatments The Papillon+™ X-ray Brachytherapy System is designed to deliver targeted, high-dose, low energy X-rays directly to the tumour or tumour bed while preserving healthy tissue, offering patients effective treatment options with no long-term side effects. Due to the precision of the Papillon+™ system, its
clinical applications are being used across Europe. Whilst Papillon CXB is the main driver for the technology, the other applications are also being used to improve patient care and quality of life. The Papillon+™ is also used to treat superficial skin cancers with positive cosmetic results as well as offering breast cancer patients the chance to be cured in a day via the Interoperative (IORT) boost at point of surgery.
Mark Davies-Cousins, a Papillon patient, says “Due
to the advances in screening and detection, in most cases we are not treating cancer patients palliatively anymore and we need a better plan for the future of these patients we are saving. Cancer treatment must not just be about prevention of death but also about the preparation for life”
Media Contact: Mark Davies-Cousins Vice President of International Sales
sales@arianemedicalsystems.com
mark.davies@arianemedicalsystems.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
